Ascendis Pharma A/S

US$256.82As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ASNDHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE 118.78%
Biotechnology
Beta (5Y) 0.48
PE TTM 19.19
TSR TTM —
Mkt cap US$16.87B
ROIC 12.98%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$263
2.23%
(50.13%)
Hold 11|1|9|7|11
4Q25
1Q26
2Q26
3Q26
Earnings per share€
3.81
3.76
4.18
4.54
14.89%
2.17%
10.66%
21.65%
Revenue€B
1.050
1.057
1.076
1.107
11.59%
9.30%
5.94%
2.81%
Peers (US$16.87B)
Cap (US$)
PE
33.28B
45.84x
8.031B
39.82x
2.720B
12.41x
16.98B
20.78x
Capital
TTM
5Y
10Y
Leveragex
0.152
0.038
0.037
EBIT/Intx
0.281
0.101
0.098
Own earn%
(108.77)
(47.97)
(52.09)
Sh yield%
31.09
44.03
44.79
Owners
Insiders/Inst%
5.89
60.80
Short interest%
4.22
SBC / revenue%
2.55
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
14–19
$1 testx
0.1
Incr. ROIC%
1